Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 31, Issue 3, 2014, Pages 198-205

  Costabel, Ulrich ^a   Albera, Carlo ^b   Bradford, Williamson Z ^c   Hormel, Phil ^c   King, Talmadge E ^d   Noble, Paul W ^e   Sahn, Steven A ^f   Valeyre, Dominique ^g   Du Bois, Roland M ^h  

^a RUHRLANDKLINIK   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c InterMune Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g AVICENNE HOSPITAL   (France)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

FVC; IPF; Pirfenidone; Survival; Treatment

Indexed keywords

CARBON MONOXIDE; PIRFENIDONE; PLACEBO; ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

AGED; ANOREXIA; ARTICLE; BRONCHITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG ERUPTION; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HEADACHE; HIP RESURFACING DEVICE; HUMAN; KAPLAN MEIER METHOD; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHINOPHARYNGITIS; SINUSITIS; SURVIVAL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADULT; AUSTRALIA; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; EUROPE; IDIOPATHIC PULMONARY FIBROSIS; LUNG; LUNG DIFFUSION CAPACITY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NORTH AMERICA; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; AUSTRALIA; DISEASE PROGRESSION; EUROPE; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MIDDLE AGED; NORTH AMERICA; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; PYRIDONES; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84923857080     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157(1): 199-203.
2. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.
3. King TE, Jr, Tooze JA, Schwarz MI, Brown K, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
4. American Cancer Society. Cancer Facts& Figures 2010. Atlanta: American Cancer Society; 2010.
5. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995; 125: 779-785.
6. Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after second dose in a three-dose bleomycin-hamster model. Exp Lung Res 1998; 24: 119-132.
7. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel antifibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur J Pharmacol 2002; 446: 177-185.
8. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002; 446: 167-176.
9. Hirano A, Kanehiro A, Ono K, Tsuruta Y, Suzuki R. Pirfenidonemodulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am J Respir Cell Mol Biol 2006; 35: 366-377.
10. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008; 590: 400-408.
11. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled, trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
12. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis: A phase III clinical trial in Japan. Eur Respir J 2010; 35: 821-829.
13. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377: 1760-1768.
14. Costabel U, Albera C, Bradford WZ, et al. Analysis of Lung Function and Survival in RECAP: An Open-label Extension Study of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Abstract). Eur Respir J 2012; 40 (Suppl. 56): 511s.
15. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in Clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
16. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
17. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171(6): 639-644. Epub 2005 Jan 7.
18. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005; 127(1): 171-177.
19. Zappala CJ, Latsi PI, Nicholson AG, et al.Marginal decline in FVC is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Resp J 2010; 35(4): 830-836. Epub 2009 Oct 19.
20. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184(4): 459-466.